Find Abilify at http://3bears.bidformymeds.com Aripiprazole (/ˌɛərɨˈpɪprəzoʊl/ air-i-pip-rə-zohl; brand names: Abilify, Aripiprex) is a partial dopamine agonist of the second generation (or atypical) class of antipsychotics that is primarily used in the treatment of schizophrenia, bipolar disorder, major depressive disorder (as an adjunct), tic disorders, and irritability associated with autism.[5] It was approved by the U.S. Food and Drug Administration (FDA) for schizophrenia on November 15, 2002 and the European Medicines Agency on 4 June 2004; for acute manic and mixed episodes associated with bipolar disorder on October 1, 2004; as an adjunct for major depressive disorder on November 20, 2007;[6] and to treat irritability in children with autism on 20 November 2009.[7] Likewise it was approved for use as a treatment for schizophrenia by the TGA of Australia in May 2003.[1] Aripiprazole was developed by Otsuka in Japan, and in the United States, Otsuka America markets it jointly with Bristol-Myers Squibb. Some doctors say that, because of promotion by the pharmaceutical industry, second-generation drugs like aripiprazole, which are appropriate for a few serious psychiatric disorders, are prescribed inappropriately for conditions it may not treat effectively, such as anxiety

• published: 15 Jan 2014
• views: 4